health

How AI is supercharging drug development

It's compressing drug developers' preclinical costs and timelines by as much as 70%.

How AI is supercharging drug development

TL;DR

  • AI is compressing preclinical costs and timelines in drug development by up to 70%.
  • This is fueling demand for cutting-edge software, sequencing tools, and computer models.
  • AI streamlines the R&D process before human testing begins, making computational tools vital.
  • The goal is to generate more experimental treatments and increase the likelihood of clinical success.
  • Demand for advanced software simulating biological processes and predicting drug interactions will rise.
  • Companies are investing in 'in silico' platforms for virtual experiments and toxicity simulations.
  • New drug development programs could grow by over 10% in three to five years, with potential for $1 billion in incremental spending.
  • Skepticism exists regarding AI's ability to factor in human responses and its impact on patient outcomes.
  • China's biotech advancements pose a competitive threat to U.S. research efforts.